LARIMAR THERAPEUTICS INC
NASDAQ: LRMR (Larimar Therapeutics, Inc.)
Last update: yesterday, 9:42PM3.97
-0.03 (-0.75%)
| Previous Close | 4.00 |
| Open | 4.02 |
| Volume | 1,491,985 |
| Avg. Volume (3M) | 4,353,649 |
| Market Cap | 412,415,264 |
| Price / Book | 5.28 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Diluted EPS (TTM) | -1.51 |
| Total Debt/Equity (MRQ) | 3.37% |
| Current Ratio (MRQ) | 7.48 |
| Operating Cash Flow (TTM) | -86.89 M |
| Levered Free Cash Flow (TTM) | -52.86 M |
| Return on Assets (TTM) | -31.47% |
| Return on Equity (TTM) | -50.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Larimar Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.43% |
| % Held by Institutions | 103.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dafna Capital Management Llc | 31 Dec 2025 | 939,164 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Citigroup, 252.65%) | Buy |
| Median | 13.00 (227.46%) | |
| Low | 12.00 (Wedbush, 202.27%) | Buy |
| Average | 13.00 (227.46%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 03 Mar 2026 | 12.00 (202.27%) | Buy | 5.51 |
| 25 Feb 2026 | 11.00 (177.08%) | Buy | 5.95 | |
| Citigroup | 25 Feb 2026 | 14.00 (252.64%) | Buy | 5.95 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |